Loss to follow‐up in patients diagnosed with or treated for low‐ and high‐grade squamous intraepithelial lesions: A comparison of general practitioner‐ and gynecologist‐led surveillance
Acta Obstetricia et Gynecologica Scandinavica · 2026
DOI: 10.1111/aogs.70301 ↗At a glance
Vergleichsstudie in Acta Obstetricia et Gynecologica Scandinavica, 2026. Written by Lieke van de Kam and 4 co-authors. Institution: Department of Obstetrics and Gynecology, Amphia, Breda, the Netherlands. Major MEDLINE topics: Uterine Cervical Neoplasms, General Practitioners, Lost to Follow-Up, Uterine Cervical Dysplasia. 31 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Amphia Science Fund, Incentive Committee Catharina Hospital.
Abstract (original language)
Introduction
Cervical carcinoma can be prevented by treating precancerous lesions, which are classified as low‐grade (LSIL) and high‐grade (HSIL) squamous intraepithelial lesions. Follow‐up of patients diagnosed with LSIL or treated HSIL is typically conducted in secondary care by a gynecologist. However, this may also be conducted in a primary care setting at the general practitioner. This latter approach offers potential benefits such as lower healthcare costs and care closer to home. However, the effectiveness of follow‐up by general practitioners is unknown. Material and Methods This retrospective cohort study included patients diagnosed with LSIL or treated HSIL by the gynecologist, with no prior history of SIL or cervical cancer, who either underwent cytological follow‐up at the gynecologist or the general practitioner. The primary outcome was loss to follow‐up at 12 months for LSIL and 24 months for treated HSIL.
Results
A total of 691 patients were followed up by the gynecologist, and 1172 by the general practitioner. In the LSIL group, 38.1% (333/874) of patients followed up by a general practitioner were lost to follow‐up at 12 months, compared with 16.6% (92/554) of those followed up by a gynecologist ( p < 0.001). For treated HSIL, 44.3% (132/298) were lost to follow‐up at 24 months in the general practitioner group, versus 24.1% (33/137) in the gynecologist group ( p < 0.001).
Conclusions
Follow‐up by a general practitioner after a diagnosis of LSIL or treated HSIL is associated with nearly twice the rate of loss to follow‐up compared to follow‐up by a gynecologist.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Obstetrics and Gynecology, Amphia, Breda, the Netherlands.
- Grow Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands.
- Palga, Dutch Pathology Registry, Houten, The Netherlands.
- Department of Obstetrics and Gynecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, The Netherlands.
- Department of Obstetrics and Gynecology, Radboud University Medical Centre, Nijmegen, the Netherlands.
ORCID profiles: Jurgen Piek
Funding
- Amphia Science Fund
- Incentive Committee Catharina Hospital
Cite
APA
van de Kam, L., Siebers, A., Bekkers, R., van Hamont, D., & Piek, J. (2026). Loss to follow‐up in patients diagnosed with or treated for low‐ and high‐grade squamous intraepithelial lesions: A comparison of general practitioner‐ and gynecologist‐led surveillance. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70301
Vancouver
van de Kam L, Siebers A, Bekkers R, van Hamont D, Piek J. Loss to follow‐up in patients diagnosed with or treated for low‐ and high‐grade squamous intraepithelial lesions: A comparison of general practitioner‐ and gynecologist‐led surveillance. Acta Obstetricia et Gynecologica Scandinavica. 2026. doi:10.1111/aogs.70301
BibTeX
@article{vandeKam2026,
author = {van de Kam, Lieke and Siebers, Albert and Bekkers, Ruud and van Hamont, Dennis and Piek, Jurgen},
title = {Loss to follow‐up in patients diagnosed with or treated for low‐ and high‐grade squamous intraepithelial lesions: A comparison of general practitioner‐ and gynecologist‐led surveillance},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2026},
doi = {10.1111/aogs.70301}
}
EUVIMED